title: MicroRNAs in Ewing Sarcoma.
abstract: MicroRNAs (miRs) have emerged recently as important regulators of gene expression in the cell. Frequently dysregulated in cancer, miRs have shed new light on molecular mechanisms of oncogenesis, and have generated substantial interest as biomarkers, and novel therapeutic agents and targets. Recently, a number of studies have examined miR biology in Ewing sarcoma. Findings indicate that alterations in miR expression in Ewing Sarcoma are widespread, involve both EWS/Ets oncogenic fusion-dependent and independent mechanisms, and contribute to malignant phenotypes. miRs with prognostic potential have been identified, and several preclinical studies suggest that miR manipulation could be therapeutically useful in this aggressive disease. These and future studies of miR biology stand to expand our understanding of Ewing sarcoma pathogenesis, and may identify new biomarkers and treatment options.
authors.affiliation: Medical Scientist Training Program, University of Colorado Denver Denver, CO, USA ; Cancer Biology Graduate Program, University of Colorado Denver Denver, CO, USA ; Anschutz Medical Campus, University of Colorado Denver Denver, CO, USA.
authors.forename: Layne
authors.initials: L
authors.lastname: Dylla
authors.forename: Colin
authors.initials: C
authors.lastname: Moore
authors.forename: Paul
authors.initials: P
authors.lastname: Jedlicka
keywords: Ewing sarcoma; microRNAs; pathogenesis; prognosis; sarcoma; therapy
references.citation: Cancer Cell. 2012 Jun 12;21(6):807-21
references.pmid: 22698405
references.citation: Am J Pathol. 2009 Apr;174(4):1131-8
references.pmid: 19264914
references.citation: RNA. 2009 Aug;15(8):1443-61
references.pmid: 19561119
references.citation: Cancer Cell. 2007 May;11(5):421-9
references.pmid: 17482132
references.citation: Mol Cancer Res. 2006 Nov;4(11):851-9
references.pmid: 17114343
references.citation: Transl Res. 2011 Apr;157(4):216-25
references.pmid: 21420032
references.citation: Cancer Res. 2007 Dec 1;67(23):11111-6
references.pmid: 18056433
references.citation: BioDrugs. 2009;23(1):15-23
references.pmid: 19344188
references.citation: Nat Rev Genet. 2009 Feb;10(2):94-108
references.pmid: 19148191
references.citation: PLoS One. 2008 Apr 16;3(4):e1965
references.pmid: 18414662
references.citation: Mol Cancer Res. 2012 Aug;10(8):1098-108
references.pmid: 22723308
references.citation: PLoS One. 2011;6(8):e23592
references.pmid: 21853155
references.citation: Nature. 2004 Nov 11;432(7014):235-40
references.pmid: 15531877
references.citation: Biochem Biophys Res Commun. 2012 Sep 14;426(1):89-93
references.pmid: 22910415
references.citation: Nat Rev Mol Cell Biol. 2009 Feb;10(2):126-39
references.pmid: 19165215
references.citation: Cancer Res. 2005 Oct 1;65(19):8698-705
references.pmid: 16204038
references.citation: Lab Invest. 2009 May;89(5):597-606
references.pmid: 19290006
references.citation: Cell Death Differ. 2010 Apr;17(4):633-41
references.pmid: 20019750
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5324-9
references.pmid: 19289832
references.citation: BMC Cancer. 2010 Mar 26;10:116
references.pmid: 20346143
references.citation: Nat Rev Cancer. 2011 Nov 24;11(12):849-64
references.pmid: 22113163
references.citation: EMBO J. 2012 Dec 12;31(24):4502-10
references.pmid: 23232809
references.citation: J Pathol. 2012 Apr;226(5):796-805
references.pmid: 21960059
references.citation: Biochim Biophys Acta. 2010 Apr;1805(2):209-17
references.pmid: 19931352
references.citation: Int J Cancer. 2010 Sep 1;127(6):1295-307
references.pmid: 20104521
references.citation: Oncogene. 2013 Sep 26;32(39):4646-55
references.pmid: 23128393
references.citation: Cancer Res. 2009 May 15;69(10):4363-71
references.pmid: 19417137
references.citation: Cancer Res. 2009 Mar 1;69(5):1776-81
references.pmid: 19208848
references.citation: Nat Med. 2010 Oct;16(10):1134-40
references.pmid: 20871609
references.citation: Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20471-6
references.pmid: 21059911
references.citation: Int J Clin Exp Pathol. 2010 Mar 19;3(4):338-47
references.pmid: 20490326
references.citation: Cancer Res. 2005 Dec 15;65(24):11459-68
references.pmid: 16357154
references.citation: Cell. 2009 Jan 23;136(2):215-33
references.pmid: 19167326
references.citation: Biochim Biophys Acta. 2010 Nov;1803(11):1231-43
references.pmid: 20619301
references.citation: Cancer Cell. 2012 Mar 20;21(3):283-96
references.pmid: 22439924
references.citation: Nat Cell Biol. 2012 Sep;14(9):958-65
references.pmid: 22864477
references.citation: Oncogene. 2016 Nov 24;35(47):6155-6156
references.pmid: 27345405
references.citation: Oncogene. 2008 Dec;27 Suppl 2:S52-7
references.pmid: 19956180
references.citation: Oncogene. 2011 May 5;30(18):2173-80
references.pmid: 21217773
references.citation: Oncogene. 2013 Aug 15;32(33):3915-21
references.pmid: 22986530
references.citation: Genes Dev. 2010 May;24(9):916-32
references.pmid: 20382729
references.citation: Cell Commun Signal. 2009 Aug 10;7:18
references.pmid: 19664273
references.citation: Nat Cell Biol. 2009 Mar;11(3):228-34
references.pmid: 19255566
references.citation: Cancer Genet. 2011 Jul;204(7):351-65
references.pmid: 21872822
references.citation: PLoS One. 2010 Nov 11;5(11):e13943
references.pmid: 21085683
references.citation: Oncogene. 2010 Aug 12;29(32):4504-16
references.pmid: 20543858
references.citation: Gene. 2005 Dec 19;363:1-14
references.pmid: 16202544
references.citation: Oncogene. 2011 Dec 8;30(49):4910-20
references.pmid: 21643012